On June 17, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small-molecule drugs targeting oncological and inflammatory diseases, reported its participation in the BIO International Convention 2026, to be held June 22–25, 2026, in San Diego, California. BIO International Convention | June 22-25 | San Diego
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
During the conference, Can-Fite will conduct partnering meetings with pharmaceutical companies, biotechnology firms, and potential strategic partners to discuss licensing and commercialization opportunities for its advanced clinical-stage pipeline.
The Company’s lead drug candidate, Namodenoson, is currently being evaluated in a pivotal Phase III study for advanced hepatocellular carcinoma (HCC), in pancreatic cancer following the successful completion of a Phase IIa study and conducting a Phase IIb study for MASH. Piclidenoson, Can-Fite’s drug candidate for inflammatory diseases, is currently being evaluated in a pivotal Phase III study for psoriasis and is undertaking the preparatory work for a Phase II study in the rare genetic disease, Lowe Syndrome.
Can-Fite’s proprietary A3 adenosine receptor (A3AR) platform technology has demonstrated a favorable safety profile in more than 1,600 patients treated to date and serves as the foundation for the Company’s pipeline of orally administered therapies targeting cancer, liver, and inflammatory diseases.
The Company has established multiple regional licensing agreements for its drug candidates and continues to pursue strategic partnerships to maximize the global value of its pipeline. To date, these agreements have generated approximately $20 million in upfront and milestone payments, with the potential for additional milestone payments and royalties.
"BIO International Convention is one of the most important partnering events in the biotechnology industry, bringing together companies seeking innovative therapeutic assets and strategic collaborations," said Dr. Sari Fishman, Vice President of Business Development at Can-Fite BioPharma. "With two pivotal Phase III programs, an ongoing Phase IIb study in MASH, and additional opportunities in oncology and rare diseases, we look forward to meeting with potential partners to discuss licensing, commercialization, and value-creating collaborations for our clinical-stage assets."
Dr. Fishman will be available for partnering meetings throughout the conference.
(Press release, Can-Fite BioPharma, JUN 17, 2026, View Source [SID1234668774])